Protagonist Therapeutics, Inc. (PTGX)

10.00
0.16 1.63
NASDAQ
Prev Close 9.84
Open 9.87
Day Low/High 9.73 / 10.47
52 Wk Low/High 5.49 / 23.97
Volume 49.03K
Exchange NASDAQ
Shares Outstanding 23.35B
Market Cap 240.24M
Div & Yield N.A. (N.A)

Latest News

Protagonist Therapeutics To Announce Fourth Quarter And Full Year 2018 Financial Results

Protagonist Therapeutics To Announce Fourth Quarter And Full Year 2018 Financial Results

-- Management to host conference call at 4:30 p.m. EDT on March 12, 2019 --

Protagonist Therapeutics Reports Granting Of Inducement Award

Protagonist Therapeutics Reports Granting Of Inducement Award

NEWARK, Calif., Jan.

Protagonist Therapeutics Initiates Phase 2 Trial Of Novel Hepcidin Mimetic PTG-300 For The Treatment Of Patients With Beta Thalassemia

Protagonist Therapeutics Initiates Phase 2 Trial Of Novel Hepcidin Mimetic PTG-300 For The Treatment Of Patients With Beta Thalassemia

-- Initial Phase 2 results expected in the second half of 2019 --

Protagonist Therapeutics Initiates Phase 1 Trial Of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943

Protagonist Therapeutics Initiates Phase 1 Trial Of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943

-- PN-10943 begins clinical development as a potential novel oral therapy for patients with inflammatory bowel disease --

Protagonist Therapeutics Enters Oversold Territory (PTGX)

Protagonist Therapeutics Enters Oversold Territory (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Protagonist Therapeutics Announces New Development Candidate PN-10943 For The Treatment Of Inflammatory Bowel Disease

Protagonist Therapeutics Announces New Development Candidate PN-10943 For The Treatment Of Inflammatory Bowel Disease

-- Oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide PN-10943 has demonstrated greater potency and target engagement in preclinical studies as compared to PTG-100 --

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALK, ARCO, BIOS, CRD.A, DCO, GNE, KEYW, LOGM, OUT, SIGA, TBBK, TGP, TPIC, XXII Downgrades: ADS, BYD, CCS, ENTA, HL, ICBK, MTW, XOMA Initiations: BPMP, PTGX Read on to get TheStreet Quant Ratings' detailed report:

Protagonist Therapeutics Reports Third Quarter 2018 Financial Results And Provides Corporate Update

Protagonist Therapeutics Reports Third Quarter 2018 Financial Results And Provides Corporate Update

-- Clinical, endoscopic, histologic and biomarker data are consistent with a dose-related clinical efficacy response of PTG-100 in the PROPEL Phase 2 ulcerative colitis study, providing support for PTG-100 as a well-tolerated, oral, gut-restricted alpha-4-beta-7-integrin-targeted therapy --

Protagonist Therapeutics Announces Completion Of Phase 1 Clinical Trial Of Oral IL-23 Receptor Antagonist PTG-200

Protagonist Therapeutics Announces Completion Of Phase 1 Clinical Trial Of Oral IL-23 Receptor Antagonist PTG-200

-- Results in normal healthy volunteers provide safety, pharmacokinetic and pharmacodynamic data --

Oversold Conditions For Protagonist Therapeutics (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Protagonist Therapeutics (PTGX)

Oversold Conditions For Protagonist Therapeutics (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Protagonist Therapeutics Inks License Pact With Johnson & Johnson's Janssen

Protagonist Therapeutics Inks License Pact With Johnson & Johnson's Janssen

The license and collaboration deal for Protagonist's PTG-200 is worth up to to $990M plus royalties.

Protagonist Therapeutics Becomes Oversold (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Protagonist Therapeutics is Now Oversold (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Protagonist Therapeutics is Now Oversold (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Oversold Conditions For Protagonist Therapeutics (PTGX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TheStreet Quant Rating: D (Sell)